Molecular characterization of clinical responses to PD‐1/PD‐L1 inhibitors in non‐small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD‐1 inhibitors in Chinese patients

According to multiple studies, the objective response rate of PD‐1/PD‐L1 inhibitors in the second‐line treatment of unscreened non‐small cell lung cancer (NSCLC) is only approximately 20%. Predictive biomarkers of treatment efficacies are still under investigation. In selected NSCLC patients with PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Peng, Cui, Xiaoxia, Bai, Li, Zhou, Xiangdong, Zhu, Xiaoli, Zhang, Jian, Jin, Faguang, Zhao, Jianping, Zhou, Chengzhi, Zhou, Yanbin, Zhang, Xiaoju, Wang, Kai, Wang, Qi, Yu, Yao, Zhang, Xiaoyu, Bai, Chunxue, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500968/
https://www.ncbi.nlm.nih.gov/pubmed/31016875
http://dx.doi.org/10.1111/1759-7714.13078

Ejemplares similares

Ejemplares similares